Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer [Yahoo! Finance]
Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)
Company Research
Source: Yahoo! Finance
retinal diseases and geographic atrophy (GA), today announced that Ray Kaczmarek has joined the company as Chief Technology and Manufacturing Officer. Mr. Kaczmarek is a recognized expert in gene therapy manufacturing with decades of experience leading operations, technology, and commercial supply strategies at pharmaceutical and biotechnology companies. "Ray brings a wealth of expertise in building and sustaining gene therapy manufacturing programs. His operational leadership will be crucial to developing the commercial supply of our future therapies as we advance towards potential commercialization," said Sulagna Bhattacharya , Co-founder and Chief Executive Officer of Nanoscope. Mr. Kaczmarek has an extensive background of executive leadership and operational expertise in the gene therapy manufacturing industry. Most recently, he served as Chief Executive Officer of Genezen, a contract development and manufacturing organization (CDMO) specializing in viral vector process develo
Show less
Read more
Impact Snapshot
Event Time:
MRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRVI alerts
High impacting Maravai LifeSciences Holdings, Inc. - Class A common stock news events
Weekly update
A roundup of the hottest topics
MRVI
News
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock.MarketBeat
- Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of DirectorsGlobeNewswire
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $4.25 price target on the stock.MarketBeat
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
- Maravai LifeSciences Announces November 2024 Investor Conference ScheduleGlobeNewswire
MRVI
Earnings
- 11/7/24 - Beat
MRVI
Sec Filings
- 12/18/24 - Form 8-K
- 12/17/24 - Form 4
- 12/9/24 - Form 4
- MRVI's page on the SEC website